Showing results (491-500 of 674) with videos related to

Sort By:
Pageof 68
Intestinal Research|May 7, 2024
Efficacy of serum leucine-rich alpha-2 glycoprotein in predicting findings of Crohn's disease small bowel lesion in capsule endoscopyTeppei Omori, Miki Koroku, Shun Murasugi, et al.
Intestinal Research|August 28, 2023
Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a reviewSung Wook Hwang, Min Kyu Kim, Mi-Na Kweon
Intestinal Research|April 20, 2026
One-year effectiveness and safety of ustekinumab treatment in patients with ulcerative colitis: an Asan-Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD) multicenter real-world cohort studyJi Eun Baek, Min Kyu Kim, Eun Soo Kim, et al.
Intestinal Research|April 20, 2026
Impact of Portulaca oleracea L. extract in patients with irritable bowel syndromeKwangwoo Nam, Jung Ho Choi, Yong Sung Kim, et al.
Intestinal Research|June 1, 2026
Rapid diagnosis and therapeutic mitigation in inflammatory bowel disease: utilizing the window of opportunity-findings from the UAE Epi-IBD studyThaer Khaleel Swaid, Layth Raafat Hamzeh, Laurette L Bukasa, et al.
Intestinal Research|May 19, 2026
Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel diseaseHsin-Yun Wu, Zhi-Che Chen, Meng-Tzu Weng, et al.
Intestinal Research|May 7, 2026
Dyslipidemia and hyperglycemia synergistically increase the risk of intestinal barrier dysfunction: evidence from a case-control study in ChinaChao Zhang, Dandan Lin, He Yu, et al.
Intestinal Research|June 4, 2025
The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective studyTaku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, et al.
Intestinal Research|February 5, 2020
The prevalence of sarcopenia and its effect on prognosis in patients with Crohn's diseaseChan Hyung Lee, Hyuk Yoon, Dong Jun Oh, et al.
Intestinal Research|July 10, 2026
Efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn's disease: a small subpopulation analysis of UNITI/IM-UNITI long-term extension through 5 yearsByong Duk Ye, Ken Sugimoto, Jae Hee Cheon, et al.
Pageof 68